SQZ Biotechnologies Shares Advance 44% on Continued AAC Trial

marketwatch2023-03-23

By Denny Jacob

SQZ Biotechnologies Co. shares advanced 44% to 87 cents in aftermarket trading Wednesday on news that its Phase 1 SQZ-AAC-HPV-101 clinical trial would continue.

Shares, which closed up 1.1% to 60 cents, are down nearly 89% over the last 12 months.

The clinical-stage biotechnology company said its trial would continue following an observation of a confirmed complete response in the first patient in its lowest-dose cohort.

"We remain focused on optimizing the potential of our eAPC and AAC platforms to meet the significant unmet medical needs of patients with HPV16+ tumors," said interim Chief Executive Howard Bernstein. Data from both of these programs will come later in the year, he said.

The trial is testing SQZ's activating antigen carriers, derived from red blood cells, to treat HPV16+ advanced or metastatic solid tumors.

Write to Denny Jacob at denny.jacob@wsj.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2321137769?lang=en_US&edition=fundamental","thumbnail":"https://images.barrons.com/im-749171?size=1.777777777777778&width=220 220w","is_english":true,"pubTime":"2023-03-23 05:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2321137769","market":"us","top_or_hot":-1,"title":"SQZ Biotechnologies Shares Advance 44% on Continued AAC Trial","media":"marketwatch","content":"<html><body><div itemprop=\"articleBody\" role=\"document\"> <div> <div> <div aria-hidden=\"true\"></div> </div> </div> <p>By Denny Jacob</p> <p>SQZ Biotechnologies Co. shares advanced 44% to 87 cents in aftermarket trading Wednesday on news that its Phase 1 SQZ-AAC-HPV-101 clinical trial would continue.</p> <p>Shares, which closed up 1.1% to 60 cents, are down nearly 89% over the last 12 months.</p> <div> <p>The clinical-stage biotechnology company said its trial would continue following an observation of a confirmed complete response in the first patient in its lowest-dose cohort.</p> <p>\"We remain focused on optimizing the potential of our eAPC and AAC platforms to meet the significant unmet medical needs of patients with HPV16+ tumors,\" said interim Chief Executive Howard Bernstein. Data from both of these programs will come later in the year, he said.</p> <p>The trial is testing SQZ's activating antigen carriers, derived from red blood cells, to treat HPV16+ advanced or metastatic solid tumors.</p><pre></pre> <p>Write to Denny Jacob at denny.jacob@wsj.com</p><pre></pre> </div> </div></body></html>","source":"mwatch_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SQZ Biotechnologies Shares Advance 44% on Continued AAC Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSQZ Biotechnologies Shares Advance 44% on Continued AAC Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-23 05:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/sqz-biotechnologies-shares-advance-44-on-continued-aac-trial-7e2ec775?mod=newsviewer_click><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob SQZ Biotechnologies Co. shares advanced 44% to 87 cents in aftermarket trading Wednesday on news that its Phase 1 SQZ-AAC-HPV-101 clinical trial would continue. Shares, which closed up ...</p>\n\n<a href=\"https://www.marketwatch.com/story/sqz-biotechnologies-shares-advance-44-on-continued-aac-trial-7e2ec775?mod=newsviewer_click\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AAC","symbol_name":"AAC Holdings, Inc.","start_time":0,"source_url":"https://www.marketwatch.com/story/sqz-biotechnologies-shares-advance-44-on-continued-aac-trial-7e2ec775?mod=newsviewer_click","article_id":"2321137769","we_media_id":null,"thumbnails":["https://images.barrons.com/im-749171?size=1.777777777777778&width=220 220w"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2321137769","pubTimestamp":1679519520,"columns":[],"sourceInfo":{"source_id":"mwatch_stock","name":"Market Watch"},"weMediaInfo":null,"summary":"By Denny Jacob SQZ Biotechnologies Co. shares advanced 44% to 87 cents in aftermarket trading Wednes","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AAC":"AAC Holdings, Inc.","BK4535":"淡马锡持仓","BK4561":"索罗斯持仓","BK4139":"生物科技"},"translate_title":"SQZ生物技术公司股价上涨44%，继续AAC试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAC":1,"SQZ":1},"content_text":"By Denny Jacob SQZ Biotechnologies Co. shares advanced 44% to 87 cents in aftermarket trading Wednesday on news that its Phase 1 SQZ-AAC-HPV-101 clinical trial would continue. Shares, which closed up 1.1% to 60 cents, are down nearly 89% over the last 12 months.  The clinical-stage biotechnology company said its trial would continue following an observation of a confirmed complete response in the first patient in its lowest-dose cohort. \"We remain focused on optimizing the potential of our eAPC and AAC platforms to meet the significant unmet medical needs of patients with HPV16+ tumors,\" said interim Chief Executive Howard Bernstein. Data from both of these programs will come later in the year, he said. The trial is testing SQZ's activating antigen carriers, derived from red blood cells, to treat HPV16+ advanced or metastatic solid tumors. Write to Denny Jacob at denny.jacob@wsj.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2321137769","isCrawlerRequest":true}